TITLE

EUROPEAN COMMISSION APPROVES ZEVALIN RADIOIMMUNOTHERAPY

PUB. DATE
March 2004
SOURCE
Worldwide Biotech;Mar2004, Vol. 16 Issue 3, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents information on the marketing approval for Zevalin radioimmunotherapy of Biogen Idec granted by the European Commission.
ACCESSION #
12391245

 

Related Articles

  • FDA Approvals In March.  // BioWorld Insight;4/15/2013, Vol. 21 Issue 16, p7 

    A table is presented which lists several drugs approved by the U.S. Food and Drug Administration along with their companies including Biogen Idec Inc, Cangene Corp and Genentech Inc.

  • Tecfidera to Treat MS.  // Monthly Prescribing Reference;May2013, Vol. 29 Issue 5, pA-27 

    The article informs that the dimethyl fumarate capsules Tecfidera from Biogen Idec Inc. has been approved for the oral treatment of multiple sclerosis (MS).

  • Big expectations for Biogen's small MS drug.  // Nature Reviews Drug Discovery;May2013, Vol. 12 Issue 5, p333 

    The article reports on the dimethyl fumarate (BG-12), a drug developed by the pharmaceutical firm Biogen Idec for the treatment of relapsing-remitting multiple sclerosis (RRMS) that was approved by the European and U.S. legislators.

  • FDA: Complete Response for Rituxan in CLL.  // Bioworld Week;11/23/2009, Vol. 17 Issue 47, p5 

    The article reports on the status of biopharmaceutical firms Genetech Inc. and Biogen Idec Inc.'s drug application approval for Rituxan to treat chronic lymphocytic leukemia (CLL) in the U.S. It mentions that the Food and Drug Administration (FDA) has delayed its decision to approve the drug due...

  • Non-U.S. Clinical Trials & Regulatory Actions: March 2013.  // BioWorld Insight;4/15/2013, Vol. 21 Issue 16, p24 

    A table is presented which represents several pharmaceutical companies other than the U.S. along with drug approval and regulatory actions update as of March 2013 including Baxter International Inc., Halozyme Therapeutics Inc. and Biogen Idec Inc.

  • FDA Submissions, Approvals & Other Actions: March 2013.  // BioWorld Insight;4/15/2013, Vol. 21 Issue 16, p27 

    A table is presented which represents several pharmaceutical companies along with drug approval and regulatory actions update as of March 2013 including Biogen Idec Inc., Acceleron Pharma Inc. and A.P. Pharma Inc.

  • COMPANY SPOTLIGHT - Biogen Idec.  // PharmaWatch: CNS;Jul2012, Vol. 11 Issue 7, p42 

    The article profiles Biogen Idec Inc. which is a biotechnology company that focuses on the development, manufacturing and marketing of drugs. It says that the U.S. Food and Drug Administration has accepted the Biogen's new drug application (NDA) for the review of BG-12, or dimethyl fumarate. The...

  • Approvals.  // BioPharm International;Jan2005, Vol. 18 Issue 1, p10 

    Reports on news and developments concerning the pharmaceutical industry. Biogen Idec and Elan's receipt of the U.S. Food and Drug Administration approval of Tysabri for reducing relapses in multiple sclerosis; FDA approval of Amgen's Kepivance, a recombinant human keratinocyte growth factor, for...

  • Two New Approvals in Blockbuster Drug Arena. Mirasol, Feliza // Chemical Market Reporter;12/6/2004, Vol. 266 Issue 19, p16 

    This article reports that biotechnology companies Genentech Inc. and Biogen Idec Inc. are dosing the year with good news — early approvals of their two likely products, tarceva and tysabri, formerly referred to as antegren. Last month the U.S. Food and Drug Administration completed its...

  • BIOGEN IDEC.  // Contract Pharma;Jul/Aug2013, Vol. 15 Issue 6, p112 

    The article profiles biopharmaceutical company Biogen Idec (BI), which is one of the top 10 biopharmaceuticals with highest revenue as of 2012. It discusses the company's net income, budget on research and development (R&D), and the top selling drugs. It mentions that BI is awaiting for an...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics